Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

De Felice, F., Marchetti, C., Palaia, I., Ostuni, R., Muzii, L., Tombolini, V., Benedetti Panici, P., Immune check-point in cervical cancer, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, n/a; 129 (N/A): 40-43. [doi:10.1016/j.critrevonc.2018.06.006] [http://hdl.handle.net/10807/203893]

Immune check-point in cervical cancer

Marchetti, C.;
2018

Abstract

Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.
Inglese
De Felice, F., Marchetti, C., Palaia, I., Ostuni, R., Muzii, L., Tombolini, V., Benedetti Panici, P., Immune check-point in cervical cancer, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, n/a; 129 (N/A): 40-43. [doi:10.1016/j.critrevonc.2018.06.006] [http://hdl.handle.net/10807/203893]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/203893
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 29
social impact